16:51 , May 15, 2019 |  BC Innovations  |  Translation in Brief

Lentiviral gene therapy could offer relief to refractory epilepsy patients

Within a year, University College London researchers hope to begin a clinical trial of a gene therapy for epilepsy, a non-monogenic disorder. The hope is that the approach will offer an alternative to brain surgery...
23:05 , May 2, 2019 |  BC Innovations  |  Translation in Brief

Public funding highlights

Public funding highlights Selected developments and initiatives in 1Q19 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
22:58 , Apr 25, 2019 |  BC Innovations  |  Emerging Company Profile

Cell Mogrify directly reprograms cells in vivo

Mogrify is jumping ahead of the technologies that have propelled the stem cell field by creating a platform that bypasses intermediate steps, and opens the door to in vivo reprogramming. Cell Mogrify Ltd. uses small...
20:41 , Mar 7, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: February 2019

New Therapeutic Targets and Biomarkers: February 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February. Therapeutic targets are defined as any protein, gene or other molecule...
01:26 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies suggest inhibiting the Wnt enhanceosome components BCL9, PYGO1 and/or PYGO2 could help treat APC-mutant colorectal cancer. In a mouse model of APC-mutant colorectal cancer, intestinal epithelium-specific knockout of BCL9, PYGO1...
21:46 , Jan 17, 2019 |  BC Innovations  |  Finance

Public funding highlights

Public funding highlights Selected developments and initiatives in 4Q18 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
16:39 , Oct 26, 2018 |  BC Week In Review  |  Company News

Dementia Discovery Fund, UK Dementia Research Institute partner to fund dementia research

The Dementia Discovery Fund (DDF) and UK Dementia Research Institute launched a partnership dubbed D3A to grant multiple awards of £100,000-£200,000 ($130,768-$261,536) to support clinical translation. D3A will fund translational projects from UK Dementia Research...
17:18 , Oct 24, 2018 |  BC Extra  |  Company News

Dementia Discovery Fund, UK Dementia Research Institute partner to fund dementia research

The Dementia Discovery Fund (DDF) and UK Dementia Research Institute launched a partnership dubbed D3A to grant multiple awards of £100,000-£200,000 ($130,768-$261,536) to support clinical translation. D3A will fund translational projects from UK Dementia Research...
01:51 , Oct 12, 2018 |  BC Innovations  |  Targets & Mechanisms

Adult path for mitochondrial gene editing

Two parallel studies show gene editing can target mutant mitochondria in adult mice, providing an alternative path for drug developers to the controversial approach of modifying embryos. In back-to-back papers published in Nature Medicine on...
22:19 , Oct 11, 2018 |  BC Innovations  |  Translation in Brief

Public funding highlights: 3Q18

Public funding highlights: 3Q18 Selected developments and initiatives in 3Q18 from major sources of public funding including NIH , the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes of Health...